Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
Accrued Liabilities
Ocular Therapeutix Inc
Accrued Liabilities Peer Comparison
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Accrued Liabilities
$17.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
30%
|
CAGR 10-Years
38%
|
|
Johnson & Johnson
NYSE:JNJ
|
Accrued Liabilities
$28.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accrued Liabilities
$9.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
Pfizer Inc
NYSE:PFE
|
Accrued Liabilities
$2.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Merck & Co Inc
NYSE:MRK
|
Accrued Liabilities
$13.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
Eli Lilly and Co
NYSE:LLY
|
Accrued Liabilities
$10.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
See Also
What is Ocular Therapeutix Inc's Accrued Liabilities?
Accrued Liabilities
17.6m
USD
Based on the financial report for Mar 31, 2024, Ocular Therapeutix Inc's Accrued Liabilities amounts to 17.6m USD.
What is Ocular Therapeutix Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
38%
Over the last year, the Accrued Liabilities growth was -26%. The average annual Accrued Liabilities growth rates for Ocular Therapeutix Inc have been 5% over the past three years , 30% over the past five years , and 38% over the past ten years .